Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Sarnacchiaro

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Endocrinological Investigation|December 31, 1997
Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjectsF Sarnacchiaro, A Colao, B Merola, et al.
European Journal of Endocrinology|November 1, 1996
Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic malesA Colao, M De Rosa, F Sarnacchiaro, et al.
The Journal of Clinical Endocrinology and Metabolism|November 14, 1997
Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkageA Colao, A Di Sarno, M L Landi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1994
CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic statesB Merola, F Sarnacchiaro, A Colao, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|September 1, 1994
Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptineB Merola, F Sarnacchiaro, A Colao, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Endocrinological Investigation|December 31, 1997
Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjectsF Sarnacchiaro, A Colao, B Merola, et al.
European Journal of Endocrinology|November 1, 1996
Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic malesA Colao, M De Rosa, F Sarnacchiaro, et al.
The Journal of Clinical Endocrinology and Metabolism|November 14, 1997
Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkageA Colao, A Di Sarno, M L Landi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1994
CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic statesB Merola, F Sarnacchiaro, A Colao, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|September 1, 1994
Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptineB Merola, F Sarnacchiaro, A Colao, et al.
Pageof 2